Varian Launches IntelliBlate in Europe to Elevate Image-Guided Cancer Therapy with Integrated Microwave Ablation

Varian, a Siemens Healthineers company, has announced the European launch of IntelliBlate, its next-generation microwave ablation solution for treating soft tissue tumors. IntelliBlate marks a significant advancement in providing clinicians and patients across Europe with a streamlined, intuitive, and minimally invasive treatment option.

Engineered for enhanced precision, control, and predictability, IntelliBlate is designed to anchor a fully integrated ecosystem for microwave ablation. It works in synergy with Siemens Healthineers’ imaging and software tools, including:

• myAblation Guide – for treatment planning and post-procedure verification;
• myNeedle Laser guidance system – which aids in accurate needle placement using CT imaging;
• Ultrasound integration – for real-time assessment, placement, and monitoring during the procedure.

Together, these tools create a seamless clinical workflow that enables physicians to plan, place, treat, monitor, and confirm ablation therapy within a single environment, improving efficiency and supporting confidence in clinical decisions.

IntelliBlate is also built with flexibility in mind, enabling personalized treatment tailored to each patient’s clinical needs. It delivers large, spherical ablation zones with high precision, supporting consistent and predictable results. A standout feature is its Ximitry probe, equipped with thermocouples that continuously measure temperature both inside and around the ablation area. This real-time thermal feedback allows clinicians to monitor temperature changes and adjust the procedure as needed for optimal outcomes.

The system provides two generators in one system, making it compact and portable. The intuitive interface with fast setup and pre-programmed ablation zone settings makes the IntelliBlate a streamlined solution that helps reduce procedural barriers.

IntelliBlate, which received its FDA market clearance in 2024, enters the European market at a time of growing clinical evidence around thermal ablation.

“The results of the COLLISION trial mark a milestone in how we think about ablation,” said Franck Facchini, President of Interventional Solutions at Varian. “We have reached the point where the clinical evidence unrefutably supports the use of thermal ablation as a first-line treatment option, and not just an option for patients who cannot undergo surgery. IntelliBlate was designed to meet this shift in care, combining precision with intelligent software and imaging in a solution that fits seamlessly into modern cancer care workflows.”

IntelliBlate will be introduced to the European clinical community in September at CIRSE 2025, the leading European Congress for interventional radiology.